

## LIPIDOLOGY AND ATHEROSCLEROSIS

## Workshop

Room: to be defined

Organizers:

Livia Pisciotta, Elda Favari (MIGHTY MEDIC society)

WEDNESDAY, MAY 17<sup>th</sup> 2017

Programme

Chairs: **Livia Pisciotta** (Genoa, Italy), **Elda Favari** (Parma, Italy)

- 1.00 pm Homozygous Familial Hypercholesterolemia (Ho-FH): updates of prevalence, genetics and therapeutical approaches, **Claudia Stefanutti** (Rome, Italy) | Abstract 5.05
- 1.25 pm Clinical management of Heterozygous Familial Hypercholesterolemia (FH), **Handrean Soran** (Manchester, UK) | Abstract 5.08
- 1.50 pm New therapeutical strategies in statin intolerant He-FH patients, **Patrizia Lopena** (Genoa, Italy) | Abstract 5.10
- 2.00 pm Circulating miR-200c is up-regulated in pediatric patients with familial hypercholesterolemia and correlates with miR-33a and miR-33b levels, **Alessandra Magenta** (Rome, Italy) | Abstract 5.09
- 2.10 pm Hypertriglyceridemia in the genomic era: risk of ischemic heart disease and pancreatitis, **Anne Tybjaerg Hansen** (Copenhagen, Denmark)
- 2.35 pm HDL, SR-BI and PCPE2: Novel partners in bi-directional cholesterol transport in adipose tissue, **Mary Sorcy-Thomas** (Milwaukee, USA) | Abstract 5.02
- 3.00 pm Q & A
- 3.30 pm Role of autoimmunity against HDL, **Nicholas Vuilleumier** (Geneva, Switzerland) | Abstract 5.01
- 3.55 pm Anti-Apolipoprotein A1 autoantibodies disrupt the cholesterol pathway via Srebp-2 and decrease circulating miR-33a in hypercholesterolaemic children, **Sabrina Pagano** (Geneva, Switzerland) | Abstract 5.06
- 4.05 pm Gene expression analysis of scavenger receptors class B in pathogenesis of atherosclerosis, **Nurfiya Davlyatshina** (Kazan, Russia) | Abstract 5.07
- 4.15 pm HDL functionality as a new possible clinical biomarker, **Elda Favari** (Parma, Italy) | Abstract 5.03
- 4.40 pm HDL from chronic kidney disease exhibits an increase in sphingosine-1-phosphate content and superior oxidative stress protection in vitro, **Miguel Frias** (Geneva, Switzerland) | Abstract 5.04
- 4.50 pm Elevated circulating PCSK9 concentrations predict subclinical atherosclerotic and metabolic changes in low risk obese and non-obese patients, **Stefan Toth** (Košice, Slovak Republic) | Abstract 5.11
- 5.00 pm **End of Session**

Starting 3 p.m. a coffee station will be available

With the contribution of:

AMGEN

SANOFI

AMRYT PHARMA

### GENERAL INFORMATION

The Workshop was credited for **60 pax** for **4 hours** and **4 credits** for the following professional categories:  
Cardiology, Endocrinology, Gastroenterology, Diabetology, Nephrology, Internal Medicine, General Medicine (family doctors).

For more information, check the web site [esci2017.grupposymposia.it](http://esci2017.grupposymposia.it)